Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Review clarifies depression, anxiety risk among hidradenitis suppurativa patients

Publish date:: June 5, 2019

Key clinical point: Depression and anxiety are common comorbidities in patients with hidradenitis suppurativa (HS).

Major finding: The prevalence of depression and anxiety, respectively, in HS patients was 16.9% and 4.9%.

Study details: The data come from a systematic review and meta-analysis of studies that included 40,307 adults with HS.

Disclosures: Dr. Machado had no financial conflicts to disclose. Several coauthors disclosed relationships with Galderma, LEO Pharma, Janssen, Novartis, AbbVie, Celgene, Naos, Lilly, Sanofi, Valeant, and La Roche–Posay.

Citation:

Machado M et al. JAMA Dermatol. 2019 June 5. doi: 10.1001/jamadermatol.2019.0759.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Anxiety Disorders

Rap music mention of mental health topics more than doubles,

Mental health risks rise with age and stage for gender-incongruent youth,

Teen affective disorders raise risk for midlife acute MI,

Divergent COVID-19 mental health impacts seen in Spain and China,

Atopic dermatitis in adults, children linked to neuropsychiatric disorders,